Literature DB >> 575159

Effect of morphine on dopaminergic neurons in the rat basal forebrain and striatum.

P Moleman, J Bruinvels.   

Abstract

Administration of morphine (20 mg/kg i.p.) resulted in an increase in the rate of dopamine (DA) loss by ca. 40% in the forebrain cortex of rats, when the drug was administered 30 min after treatment with the synthesis inhibitor alpha-methyl-para-tyrosine methylester (alpha-MpT). This effect was specific as it was antagonized by naloxone. In the same rats the rate of DA loss in the striatum was unaltered. It was shown that this differential effect was not due to a delayed inhibition of DA synthesis in the forebrain cortex when compared with the striatum. When morphine, on the other hand, was administered before inhibition of DA biosynthesis (30 min before alpha-MpT) an increase in the rate of DA loss was also observed in the striatum and a more marked increase was seen in the forebrain cortex. Sub-dissection of the forebrain cortex showed that most of the DA (80%) was present in basal parts of the forebrain and not in the frontal or cingulate cortex. The results suggest, therefore, that morphine administration results in DA release in basal parts of the forebrain, but not in the striatum.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 575159     DOI: 10.1007/bf01250788

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  21 in total

1.  A role for the amygdala in the development of the cataleptic and stereotypic actions of the narcotic agonists and antagonists in the rat.

Authors:  B Costall; R J Naylor
Journal:  Psychopharmacologia       Date:  1974-02-27

2.  The effect of narcotic analgesics on the homovanillic acid content of rat nucleus caudatus.

Authors:  L Ahtee; I Kääriäinen
Journal:  Eur J Pharmacol       Date:  1973-05       Impact factor: 4.432

Review 3.  The chemical estimation of catecholamines and their metabolites in body fluids and tissue extracts.

Authors:  H Weil-Malherbe
Journal:  Methods Biochem Anal       Date:  1971

4.  Use of catechol O-methyltransferase for the enzyme radiochemical assay of dopamine.

Authors:  A C Cuello; R Hiley; L L Iversen
Journal:  J Neurochem       Date:  1973-11       Impact factor: 5.372

5.  The determination of dopamine by a modification of the dihydroxyindole fluorimetric assay.

Authors:  C V Atack
Journal:  Br J Pharmacol       Date:  1973-08       Impact factor: 8.739

6.  Brain RNA and hypophysectomy; a topographical study.

Authors:  W H Gispen; P Schotman; E R de Kloet
Journal:  Neuroendocrinology       Date:  1972       Impact factor: 4.914

7.  Catecholamine biosynthesis in brains of rats treated with morphine.

Authors:  D H Clouet; M Ratner
Journal:  Science       Date:  1970-05-15       Impact factor: 47.728

8.  Catalepsy induced by morphine or haloperidol: effects of apomorphine and anticholinergic drugs.

Authors:  C Erzin-Waters; P Muller; P Seeman
Journal:  Can J Physiol Pharmacol       Date:  1976-08       Impact factor: 2.273

9.  Regional rat brain levels of 3,4-dihydroxyphenylacetic acid and homovanillic acid: concurrent fluorometric measurement and influence of drugs.

Authors:  B H Westerink; J Korf
Journal:  Eur J Pharmacol       Date:  1976-08       Impact factor: 4.432

10.  The effects of acutely administered analgesics on the turnover of noradrenaline and dopamine in various regions of the rat brain.

Authors:  M F Sugrue
Journal:  Br J Pharmacol       Date:  1974-10       Impact factor: 8.739

View more
  2 in total

1.  Effects of morphine on dopamine metabolism in rat striatum and limbic structures in relation to the activity of dopaminergic neurones.

Authors:  P Moleman; C F van Valkenburg; J A vd Krogt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-09       Impact factor: 3.000

2.  Retardation of cerebral dopamine turnover after morphine withdrawal and its enhanced acceleration by acute morphine administration in rats.

Authors:  L M Attila; L Ahtee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-09       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.